Figure 7. Effect of pharmacological and genetic suppression of EZH2.

(A) GSEA showing enrichment of Benporath PRC2 target signature in genes upregulated by EZH2 inhibitor GSK126. (B) GSEA showing that genes upregulated with GSK126 treatment are enriched for the top 300 genes with highest H3K27me3 ChIP-Seq signal in Kelly and LAN-1 cells. (C) GSEA showing enrichment of neuron differentiation signature in genes upregulated by GSK126. (D) GSEA showing enrichment of neuron development signature in genes upregulated by GSK126. (E) The effect of conditional knockdown of EZH2 on NGF-induced neurite outgrowth in neuroblastoma cell line NGP. Shown is immunocytochemistry with βIII-tubulin antibodies, with photographs representative of 5 fields taken at ×100 original magnification. (F) GSEA showing that genes upregulated with GSK126 treatment are enriched for genes silenced in MYCN-amplified and high-risk neuroblastoma based on primary tumor expression data sets.